

1 **Title:** A Transducing Bacteriophage Infecting *Staphylococcus epidermidis* Contributes to the Expansion
2 of a Novel Siphovirus Genus and Implies Genus is Inappropriate for Phage Therapy

3 **Authors:**

4 Taylor Andrews, J. Steen Hoyer, Karolyn Ficken, Paul D Fey, Siobain Duffy, Jeffrey M. Boyd

5 Corresponding Authors: Dr. Jeffrey Boyd (jeffboyd@sebs.rutgers.edu) Department of Biochemistry and
6 Microbiology, School of Environmental and Biological Sciences, Rutgers University, New Brunswick,
7 New Jersey, USA; Dr. Siobain Duffy (duffy@sebs.rutgers.edu) Department of Ecology, Evolution, and
8 Natural Resources, School of Environmental and Biological Sciences, Rutgers University, New
9 Brunswick, New Jersey, USA

10

11 **ABSTRACT**

12 The effort to discover novel phages infecting *Staphylococcus epidermidis* contributes to both the
13 development of phage therapy and the expansion of genome-based phage phylogeny. Here, we report
14 the genome of an *S. epidermidis*-infecting phage Lacachita and compare its genome with five other
15 phages with high sequence identity. These phages represent a novel siphovirus genus, which was
16 recently reported in the literature. The published member of this group was favorably evaluated as a
17 phage therapeutic agent, but Lacachita is capable of transducing antibiotic resistance and conferring
18 phage resistance to transduced cells. Members of this genus may be maintained within their host as
19 extrachromosomal plasmid prophages, through stable lysogeny or pseudolysogeny. Therefore, we
20 conclude that Lacachita may be temperate and members of this novel genus are not suitable for phage
21 therapy.

22 **IMPORTANCE**

23 This project describes the discovery of a culturable bacteriophage infecting *Staphylococcus epidermidis*
24 that is a member of a rapidly growing novel siphovirus genus. A member of this genus was recently
25 characterized and proposed for phage therapy, as there are few phages currently available to treat *S.*
26 *epidermidis* infections. Our data contradict this, as we show Lacachita is capable of moving DNA from
27 one bacterium to another, and it may be capable of maintaining itself in a plasmid-like state in infected
28 cells. These phages' putative plasmid-like extrachromosomal state appears to be due to a simplified
29 maintenance mechanism found in true plasmids of *Staphylococcus* and related hosts. We suggest
30 Lacachita and other identified members of this novel genus are not suitable for phage therapy.

31 **INTRODUCTION**

32 *Staphylococcus epidermidis* is a Gram-positive commensal bacterium of humans that is also an
33 opportunistic pathogen: the most common source of nosocomial infections (1). *S. epidermidis* infections
34 are becoming increasingly difficult to treat due to the prevalence of antibiotic resistant strains (2).
35 Instead of relying on continued development of new antibiotics (3), a promising alternative that is being
36 approached with renewed interest is phage therapy, which uses bacteriophages to treat bacterial
37 infections (4). Phage therapy utilizes the mechanism of lytic phage replication to kill infection-causing
38 bacteria. While phages can be modified or selected in laboratory conditions to optimize their

39 performance, phage therapy relies on the diversity of naturally occurring phages of pathogenic bacteria.
40 New phages must be isolated from the environment, characterized, and assessed for therapeutic potential
41 (5). However, phages that infect *S. epidermidis* remain largely under-sampled and under-studied,
42 especially in comparison to its relative, *Staphylococcus aureus* (6).

43 In recent years, there has been increasing research and effort to isolate *S. epidermidis* phages (7-12). As
44 part of this *S. epidermidis* phage prospecting, members of a novel genus were isolated in multiple parts
45 of the world in 2021. Fanaei Pirlar et al (13) isolated, characterized and sequenced a dsDNA siphovirus,
46 CUB-EPI_14 (ON325435.2), that is ~43kb and has a narrow host range within *S. epidermidis*. Despite
47 the genome of CUB-EPI_14 being labeled as likely temperate by PhageAI, which is normally
48 disqualifying for a potential phage for therapy (14), CUB-EPI_14 lacks an integrase and the authors
49 suggest it could be a potential candidate for phage therapy (13).

50 Simultaneous with the work of Fanaei Pirlar et al, we also isolated a related phage from this novel genus
51 by culturing wastewater on *S. epidermidis*, as did a third group, who has deposited their phage's genome
52 in GenBank without an accompanying paper (GenBank ON550478.1). We sequenced the genome of our
53 representative (Lacachita) and conducted additional host range and transduction assays. We found three
54 additional representatives of this novel genus in GenBank (including one from an *S. epidermidis* shotgun
55 sequencing project) and analyzed these with the three cultured phage genomes. We identified in all
56 genomes a common phage resistance gene and a partitioning protein that is associated with being
57 maintained in a plasmid state. Combined with our observation that Lacachita can transduce antibiotic
58 resistance genes, we propose that members of this novel genus are likely temperate and therefore
59 inappropriate for phage therapy.

60 **MATERIALS AND METHODS**

61 Wastewater Sample Screening

62 Aliquots of wastewater influent from a treatment plant in the mid-Atlantic United States were obtained
63 in March 2021 and were screened for lytic phages effective against *S. epidermidis* 1457 (15). 5mL of the
64 wastewater samples were combined with 0.15g powdered tryptic soy broth (TSB) medium, 25 μ L of 1M
65 CaCl₂, and 50 μ L bacterial broth culture (*S. epidermidis* 1457), then incubated overnight at 37°C. A
66 second sample of wastewater underwent the same procedure without the addition of host bacteria. After
67 incubation, the mixtures were centrifuged at 3220xg for 15 minutes and the supernatant was passed
68 through a 0.22 μ m filter. 100 μ L of the filtrate was cultured with 100 μ L of 10⁻¹ bacterial dilution of an
69 overnight culture using the pour plate method (in 3mL of 0.3% molten TSA combined with 25 μ L of 1M
70 CaCl₂, vortexed and poured onto TSB 1% agar plates). The plates were then incubated overnight at 37°C
71 and examined for the presence of plaques.

72 Phage Isolation

73 In order to purify phages identified during the screening process, isolated plaques were picked up using
74 a sterile glass pipette tip and the agar was deposited into a culture tube containing 2mL TSB, 50 μ L
75 bacterial broth culture, and 25 μ L of 1M CaCl₂, and was incubated overnight at 37°C. This liquid culture
76 was then centrifuged at 3220xg for 15 minutes and the supernatant was passed through a 0.22 μ m filter.
77 The filtrate was diluted, and 100 μ L of this diluted filtered supernatant was combined with 100 μ L 10⁻¹

78 bacterial dilution, 25 μ L of 1M CaCl₂, and 3mL of molten TSA, vortexed, and poured onto tryptic soy
79 agar (TSA) plates. The plates were then incubated overnight at 37°C and examined for plaques. This
80 subculturing procedure was performed a total of three times to yield a purified, enriched phage stock.

81 DNA Isolation and Sequencing

82 The DNA genome of one isolated phage was extracted using a Qiagen QIAamp MinElute Virus Spin
83 Kit. Paired end Illumina sequencing was performed at MiGS (Microbial Genome Sequencing Center,
84 now SeqCenter). Reads were analyzed using CPT Galaxy Phage genome assembler v2021.01 Workflow
85 (16), which uses SPAdes Galaxy v3.12.0 (17). This yielded three assembled contigs. These contigs were
86 aligned manually using Aliview (18) to verify that they were identical (except for short regions of
87 duplication due to the likely circular genomes having been assembled linearly) and to produce a
88 complete genome without such duplications. The Lacachita genome was reoriented to mimic the
89 linearization of relatives found using NCBI Standard Nucleotide BLAST.

90 Genome annotation

91 The Lacachita genome was annotated using Prokka (v1.14.6, Galaxy; parameters Kingdom: Viruses,
92 (19). Predicted ORFs were annotated further using NCBI Standard Protein BLAST, and the sequences
93 producing significant alignments were analyzed to determine functional gene annotations for Lacachita.
94 When the BLAST search produced multiple identical hits, we chose the annotation that was most
95 relevant to a phage lifestyle (eg: the name given in another phage genome). Phylogenetic analysis of the
96 Lacachita genome and other dsDNA phage genomes was performed with GRAViTy v1.1.0 (Genome
97 Relationships Applied to Virus Taxonomy, <http://gravity.cvr.gla.ac.uk/>), (20).

98 Further functional annotation was performed. Promoter sequences were predicted by inputting the
99 Lacachita genome into the Genome2D Prokaryote Promoter Prediction tool (21). Rho-independent
100 termination sites were predicted using the ARNold web tool (22). Noncoding RNAs were found using
101 Rfam (23). tRNAscan-SE was used to search the Lacachita genome for transfer RNAs (24).

102 Comparison to related phage genomes

103 To identify close relatives of Lacachita, the assembled Lacachita genome was used to query NCBI
104 Standard Nucleotide BLAST. Other phage relatives were identified by searching predicted Lacachita
105 ORFs using NCBI Standard Protein BLAST and making note of organisms with consistent protein
106 homology to Lacachita ORFs, whose genomes were then compared to Lacachita directly using NCBI
107 Align Sequences Nucleotide BLAST. Lacachita and identified relatives were analyzed with GRAViTy
108 v1.1.0 to determine their taxonomy (20). GRAViTy results were visualized using FigTree v1.4.4
109 (<http://tree.bio.ed.ac.uk/software/figtree/>). The protein products of Lacachita predicted ORFs were
110 analyzed to identify potential indicators of phage lifestyle, and the genomes of Lacachita and its
111 relatives were also analyzed using the PhageAI lifestyle classifier algorithm (25).

112 ParB Protein Maximum Likelihood Tree

113 Two sets of ParB-like protein sequences were collected for phylogenetic analysis: Lacachita ParB
114 BLASTp hits and annotated ParB sequences from *Staphylococcus* genomes. Sequences were aligned by
115 MUSCLE (26) and the alignment was checked by eye. The aligned sequences were used to build a

116 maximum likelihood tree with PhyML (27) on the Montpellier Bioinformatics Platform (atgc-
117 montpellier.fr/phym/). The LG substitution model with empirical amino acid frequencies and estimated
118 proportion of invariant sites were used, and 1000 bootstrap replicates were run.

119 Host Range

120 The host range of Lacachita was explored via spot plating on multiple strains of *S. epidermidis* and
121 several other *Staphylococcus* species isolates. The *S. epidermidis* strains tested were: 1457, 158-22,
122 B138-22, B72-22, B76-22, B64-22, NRS101 (RP62a), and ATCC 12228. We tested other
123 *Staphylococcus* species isolates: *S. hominis* (160-22, B124-22), *S. haemolyticus* (B1869-21, 157-22), *S.*
124 *simulans* (B149-22, B1781-21), *S. capitis* (B65-22, B1931-21), *S. lugdunensis* (B50-22), *S. warneri*
125 (B21-22), and *S. aureus* (LAC WT, SH1000, MW2, N315). With exception of *S. epidermidis* strains
126 1457, ATCC 12228, NRS101 (RP62a) and the *S. aureus* strains, the isolates are deidentified clinical
127 isolates that were collected at the University of Nebraska Medical Center Clinical Microbiology
128 Laboratory. Pour plates of each strain were prepared by combining 3mL of 0.7% molten TSA, 25 μ L of
129 1M CaCl₂, and 10 μ L bacterial overnight culture, vortexing the mixture, and pouring it onto TSA 1%
130 agar plates. Once the top agar solidified, 5 μ L of a dilution series (1 to 10⁻⁹) of high titer Lacachita lysate
131 was spotted onto the surface. As a control, 5 μ L of TSB was also spotted onto the plates. The plates were
132 then incubated overnight at 37°C and examined for evidence of lysis. Experiments were conducted in
133 triplicate.

134 Transduction

135 In order to determine whether Lacachita possesses transducing abilities, a plasmid transduction
136 experiment was performed. A modified *S. epidermidis* strain (1457 saeR/pNF155) carrying a 9kb
137 plasmid which is marked with an erythromycin resistance gene served as a donor strain and
138 erythromycin sensitive *S. epidermidis* 1457 served as a recipient strain (28). Phage-bacterial cocultures
139 were prepared with 2mL of *S. epidermidis* 1457 saeR/pNF155 overnight culture (grown in TSB with
140 10 μ g/mL erythromycin) was combined with 5mL TSB, 100 μ L 1M CaCl₂, and 100 μ L Lacachita purified
141 phage stock. These bacteria-phage cocultures were incubated overnight at 37°C. The following day,
142 Lacachita phages were harvested from the cocultures by centrifugation (13,000xg for 3 minutes) and the
143 resulting supernatant was then filtered using sterile 0.22 μ m filters to remove bacterial cells. This filtered
144 supernatant was then combined with overnight cultures of *S. epidermidis* 1457 recipient strain: 500 μ L *S.*
145 *epidermidis* 1457 culture, 500 μ L TSB, 100 μ L 1M CaCl₂, and 100 μ L of the harvested Lacachita donor
146 phage preparation. These cocultures were incubated at 37°C for 1 hour. Following incubation, 400 μ L of
147 1M sodium citrate was added to each, each tube was vortexed to mix, and each coculture was transferred
148 to a microcentrifuge tube. Cells were pelleted by centrifuging at 13,000xg for 2 minutes and the
149 supernatant was discarded. The cells were resuspended in 1mL TSB and centrifuged again at 13,000xg
150 for two minutes. The cells were then resuspended in 200 μ L TSB and plated on TSA plates containing 10
151 μ g/mL erythromycin and 2mM sodium citrate. As negative controls, erythromycin sensitive *S.*
152 *epidermidis* 1457 was plated on erythromycin-containing TSA plates and the Lacachita phage stock was
153 spotted onto erythromycin-containing TSA plates. Inoculated plates were incubated overnight at 37°C
154 and were then examined for the presence of bacterial growth. The transduction experiments were
155 performed six times.

156 Assessing Phage Resistance of Lysogenized Bacterial Cells

157 To determine whether transduced bacteria were resistant to new lytic Lacachita infection, we spotted
158 serial dilutions of Lacachita lysate onto lawns of transduced *S. epidermidis* 1457 cells. We obtained
159 transduced cells using a modification of the transduction protocol above (excluding sodium citrate from
160 the agar plates) and representative resulting colonies were streaked onto erythromycin-containing TSA
161 plates. Liquid cultures were inoculated with isolated colonies in 10mL TSB containing 10 μ g/mL
162 erythromycin and were incubated overnight at 37°C. Pour plates of lysogenized cells were prepared by
163 combining 3mL of 0.7% molten TSA, 25 μ L of 1M CaCl₂, 10 μ L bacterial overnight culture, and 3 μ L 10
164 μ g/mL erythromycin, vortexing the mixture, and pouring it onto TSA plates. Once the top agar
165 solidified, 5 μ L of a dilution series (1 to 10⁻⁹) of high titer Lacachita lysates were spotted onto the
166 surface. As a control, 5 μ L of TSB was also spotted onto the plates. For comparison, this was also
167 performed on *S. epidermidis* 1457 that had not undergone transduction and potential lysogeny. The
168 plates were then incubated overnight at 37°C and examined for evidence of lysis. Experiments were
169 conducted in triplicate.

170 **RESULTS**

171 Isolation of Lacachita

172 Phages capable of forming plaques on *S. epidermidis* 1457 were successfully isolated from samples of
173 wastewater influent from a treatment plant in the mid-Atlantic United States. Concentrated samples of
174 the unenriched wastewater did produce plaques on *S. epidermidis* 1457, but the enriched wastewater
175 produced orders of magnitude more plaques. Plating the host alone (without wastewater) did not
176 produce any plaques. During the isolation procedure, a total of 11 plaques were harvested for potential
177 further work. Of these isolated plaques, two were chosen for sequencing. Upon sequencing and
178 assembly of the genomes, it was discovered that the two were 100% identical and so only one
179 (Lacachita) was further characterized.

180 Lacachita genome and annotation

181 Lacachita has a 46,473bp dsDNA genome that is likely circular (GenBank accession OP142323). It
182 contains 72 predicted ORFs, 19 putative promoters, 1 putative noncoding RNA (which encodes a group
183 I catalytic intron), 19 putative rho-independent terminators, and no predicted tRNAs. Several similar
184 phage genomes were identified by BLAST (>95% identity over \geq 93% of the genome), and the Lacachita
185 genome was linearized and oriented to mimic the genomes of its close relatives, which were also
186 isolated on *S. epidermidis* (ON550478.1, ON325435.2, Table 1).

187 Lacachita's putative protein products contain an expected assortment of phage proteins and some
188 hypothetical proteins (Figure 1). Nine structural proteins were identified, which were similar, by
189 BLASTp, to those of siphoviruses with long, non-contractile tails. Lacachita has both a holin and an
190 endolysin, and 14 proteins involved in DNA replication and metabolism were identified. Two ORFs are
191 associated with a plasmid prophage lifestyle: a parB-like protein and a potential phage resistance
192 protein. The remaining 43 ORFs in the Lacachita genome are either hypothetical (34 ORFs), are
193 identified only with a protein family or as including a known domain (9 ORFs).

195 Lacachita is part of novel genus, along with other proposed members

196 Four other phage genomes were identified by BLASTn to be relatives of Lacachita, and another by
197 BLASTp (Table 1). Of these five relatives, only CUB-EPI_14 (ON325435.2) has yet been thoroughly
198 described (13). The authors of that paper noted that CUB-EPI_14 appears to represent a novel genus and
199 identifies two other potential members of the genus via calculation of intergenomic distance: Uncultured
200 Caudovirales phage clone 9S_3 (MF417888.1) and TPA: Myoviridae sp. isolate ct5pN1 (BK030923.1).
201 These two phages were also independently identified as relatives of Lacachita during our searches, and
202 so our analysis complements and bolsters the evidence for these phages representing a new genus. The
203 genome of another cultured phage, Sazerac (ON550478.1), was deposited in GenBank after the
204 manuscript about CUB-EPI_14 was submitted for publication, and we propose that Sazerac is also part
205 of this novel genus. The final relative, Sep_B35_CVC_2019 (NZ_CAJUVG010000006), was identified
206 due to its consistent protein sequence identity to Lacachita protein products. Although Sep_B35 is
207 catalogued in NCBI as a contig of a *S. epidermidis* whole shotgun sequence, we argue that this contig
208 represents a full phage genome from an infected *S. epidermidis* strain. Further, since the sample of *S.*
209 *epidermidis* was sequenced as a bacterial shotgun sequencing project, not labeled as a study in phage
210 infection, we suggest that the Sep_B35 genome represents a prophage that was being maintained within
211 the *S. epidermidis* isolate at the time it was sequenced.

212 Taxonomic assignment of Lacachita and its relatives confirmed that these phages represent a novel
213 genus within the family *Siphoviridae* (Figure 2). The six genomes form a monophyletic clade, clustered
214 near the *Sextaecvirus* infecting other Staphylococci, among other siphoviruses. There was strong
215 support for this group forming a novel genus (Symmetrical Theil's uncertainty correlation 0.863).
216 Genomic maps of the six members of the putative genus reveal some observable regions of synteny
217 (Figure 3).

218 Following the example of Fanaei Pirlar et al (13), we ran the six genomes through the PhageAI lifestyle
219 classifier. We found that Lacachita and all members of this putative novel genus were predicted to be
220 temperate with at least 99.95% confidence (Table 1). Three of the five proposed relatives of Lacachita
221 are uncultured, putative phages. Based on the length and query cover of these genomes compared to
222 those of cultured isolates, it is likely that these represent essentially complete genomes.

223 Host range results

224 Of the 7 *S. epidermidis* strains tested in this project, 5 μ L of Lacachita lysate was found to be capable of
225 lysing *S. epidermidis* strains 1457, NRS101 (RP62a), B72-22, 158-22, and B138-22. Of the other
226 *Staphylococcus* species strains tested, 5 μ L of Lacachita lysate was found to be capable of lysing *S.*
227 *capitis* B65-22 and B1931-21 and *S. lugdunensis* B50-22 (Table 2).

228 Lacachita is capable of transduction and lysogeny

229 Transduction assays were conducted three separate times and in 5/6 cases, Lacachita was capable of
230 transducing plasmid-encoded erythromycin resistance to erythromycin-sensitive *S. epidermidis* 1457.

231 Spotting of serial dilutions of Lacachita lysate on bacterial lawns of transduced *S. epidermidis* 1457
232 revealed that these transduced cells were 100x less susceptible to lysis compared to *S. epidermidis* 1457
233 that had not undergone transduction. While the highest dilution of the lysate able to produce lysis on *S.*

234 *epidermidis* 1457 was 10^{-6} , the highest dilution of the lysate able to lyse transduced *S. epidermidis* 1457
235 was 10^{-4} .

236 We were unable to identify a putative integrase gene in the genomes of Lacachita or its close relatives.
237 ORF analysis of Lacachita and its close relatives revealed the presence of putative *parB* and common
238 phage resistance gene (Figure 1) in all six genomes (Table 3), which is partial evidence that these phages
239 are temperate and suggests the prophages are maintained extrachromosomally. We elected to classify
240 Lacachita ORF70 (UVD33307.1) “ParB protein” because the highest BLASTp result (99.8% identity)
241 was annotated as a ParB protein (MAG TPA: ParB protein [Myoviridae sp.] DAI53229.1). We
242 conducted a phylogenetic analysis of the ParB-like proteins from this putative genus and related
243 sequences (identified by BLASTp) and annotated ParB proteins from *Staphylococcus* genomes (Figure
244 4). The sequences from Lacachita’s putative genus form a robust clade (99.7% bootstrap support), and
245 several of the more distantly related sequences from other phage genomes are also classified as ParB
246 proteins. The sister group (DAT62215.1) shares 51.2% identity and 99% query cover with Lacachita’s
247 ParB protein. While some bacterial ParB proteins were identified by the BLASTp search they were not
248 from *Staphylococcus* – the *Staphylococcus* ParB sequences formed an outgroup to the sequences
249 identified by BLASTp. Our decision to classify this ORF *parB* was bolstered by the efficiency of plating
250 results on transduced *S. epidermidis* cells; Lacachita appears to be temperate. We elected to classify
251 Lacachita ORF30 (UVD33267.1) as a “resistance protein” because its highest NCBI BLASTp result
252 (100% identity) was the “resistance protein” DAI53234.1 MAG TPA: resistance protein [Myoviridae
253 sp.]. The other BLASTp hits (within and outside of this putative genus) are from phage and
254 *Staphylococcus* proteins with Siphovirus-gp157 protein family annotations (pfam05565), members of
255 which have been experimentally shown to confer phage resistance (29, 30).
256

257 DISCUSSION

258 Lacachita is part of a novel genus.

259 Our GRAViTy analysis strongly suggests that Lacachita and its relatives belong to a siphovirus genus
260 recently described by Fanaei Pirlar et al (13), who characterized CUB-EPI_14 as belonging to a novel
261 genus along with 9S_3 and ct5pN1. We have also expanded this putative genus by two more phages:
262 Sazerac and the Sep_B35_CVC_2019 putative prophage. Based on the high genetic identity between
263 CUB-EPI_14 and the other genomes we can assume all members of this genus have long, non-
264 contractile tails (13). Members of this genus have already been found on three continents and we
265 anticipate further isolates will be characterized in the upcoming years. Additional hosts may be
266 identified for these phage as well, as we have expanded the potential hosts for members of this genus to
267 include other *Staphylococcus* species than *S. epidermidis* (relative to Fanaei Pirlar et al (13)).

268 Lacachita and its relatives are not suitable for phage therapy.

269 However, unlike Fanaei Pirlar et al (13), we do not think members of this genus should be used for
270 phage therapy. There are several characteristics that are typically screened for when assessing whether a
271 phage could be used for phage therapy, including: host range, phage virulence, transduction potential,
272 stability against environmental pressures, and the presence of toxin genes (31). Bioinformatic analysis
273 suggests members of this genus are temperate, which is contraindicated for phage therapy. Temperate
274 phages capable of transduction have the potential to increase the pathogenicity of lysogenized bacteria

275 by carrying virulence factors between hosts (32). This is observed in temperate phages of *S. epidermidis*
276 that can mobilize antibiotic resistance plasmids (33). In the interest of self-preservation, prophages also
277 typically cause lysogenized bacteria to become immune to lytic infection by other phages that share
278 similar repression systems (31). None of the members of this putative genus have an integrase gene,
279 which is a key indicator of a temperate lifestyle because it allows stable integration of the phage genome
280 into that of its host (14). Instead, the signal that PhageAI is picking up on in the phage genomes may be
281 the presence of the *parB* gene (typically found as a *parA-parB* pair, implying a ParAB-*parS* system for
282 chromosome segregation (34)) and the putative phage resistance gene, which is not required in phage
283 that only rapidly lyse their host cells (35). Some temperate phages are known to be maintained in their
284 bacterial host cells as extrachromosomal circular plasmids and maintain their presence in their hosts
285 with similar mechanisms to plasmids (35-37). Some phage prospecting projects anticipate that these
286 plasmid-like prophages may be isolated (38), but require that genomes have both *parA* and *parB*
287 partitioning protein ORFs identified to be considered temperate
288 (<https://seaphages.org/forums/topic/4367/>). To our knowledge, there are no characterized phage,
289 temperate or otherwise, that only contain a gene for ParB, which binds to specific DNA sequences
290 (*parS*, which vary among bacteria (39)). A BLASTp search with the ParB of Lacachita only found
291 members of its genus and 50% coverage to other phage proteins (typically the N-terminus of ParB, data
292 not shown). Nonetheless, we did not find a ParA homolog, which is an ATPase that assists with
293 localization of ParB (40, 41) in these six phage genomes.

294 The hosts of these phage, which is confirmed to be *Staphylococcus epidermidis* for four of these six
295 phages, may offer explanation. Members of families *Streptococcaceae* and *Staphylococcaceae* are known
296 to not use a ParAB-*parS* system to ensure their own chromosome's proper segregation into daughter
297 cells; they use a ParB-*parS* system without a ParA (39). Plasmids of these hosts have been found that
298 also use a ParBS system, such as *S. aureus* plasmid SK1 (42). Therefore, extrachromosomally
299 maintained prophages of these hosts may also not need a ParA in order to stably vertically transmit to
300 daughter cells. Our attempts to identify a *parS* site in Lacachita and its relatives, based on identity to
301 *parS* sites from *S. epidermidis* (39) have been unsuccessful. However, there is low sequence identity
302 between the ParB proteins of these phages and *S. epidermidis* and there is reason to assume that the host
303 and phage would use quite divergent *parS* sites to bind their very divergent ParB proteins. Sequenced
304 phages that encode both a ParA and ParB protein do not always identify a *parS* site (38) so we do not
305 view our inability to find a *parS* site a barrier to suggesting Lacachita and its relatives are temperate
306 phages which use a ParBS system.


307 There is no perfect test for whether a phage is temperate and capable of creating a lysogen. We
308 observed intermittent turbidity of plaques on *S. epidermidis* 1457 and in the spot plating experiments on
309 other *Staphylococcus* strains, which is often considered an important phenotype of temperate phages
310 (35). However, turbidity can be affected by many factors (35). Importantly, we have repeated evidence
311 of Lacachita's capacity to transduce erythromycin resistance to a previously susceptible strain of *S.*
312 *epidermidis*. Transduction is a phenomenon typically associated with temperate phage, though it can be
313 due to 'pseudolysogeny,' or the formation of a carrier state (43-45). Our experimental evidence of
314 Lacachita's ability to confer phage resistance to transduced cells is more indicative of lysogeny. Many
315 temperate phages do not confer complete resistance to infection with that phage and a 100-fold
316 reduction in efficiency of plating is consistent with the behavior of other temperate phages (46, 47).

- 317 Regardless of the durability of lysogeny with Lacachita, any transducing ability is empirical evidence
318 that Lacachita and its close relatives should not be used in phage therapy.
- 319 Phage therapy remains a promising avenue of research for treating *S. epidermidis* infections, but
320 members of this genus are not appropriate therapeutic agents. Genetic engineering is one way to modify
321 temperate phages to be more appropriate therapeutic candidates (48) but that approach is controversial
322 (49). Additional isolation of *S. epidermidis* phages is needed to find obligately lytic phage.
- 323 ACKNOWLEDGEMENTS:
- 324 This work was supported by NIAID 1R01AI139100-01, NSF 1750624 and USDA MRF project
325 NE-1028 to JMB and NSF 1453241 to SD. TPA was supported by NIGMS NIH 1T32GM139804-01.
326 We thank the utility partner (who wished to remain anonymous) for providing the wastewater influent.
327 We also thank two anonymous reviewers for their constructive feedback which improved the
328 manuscript.
- 329 REFERENCES
- 330 1. Gomes F, Teixeira P, Oliveira R. 2014. Mini-review: *Staphylococcus epidermidis* as the most frequent
331 cause of nosocomial infections: old and new fighting strategies. *Biofouling* 30:131-141.
- 332 2. Lee JYH, Monk IR, Gonçalves Da Silva A, Seemann T, Chua KYL, Kearns A, Hill R, Woodford N,
333 Bartels MD, Strommenger B, Laurent F, Dodémont M, Deplano A, Patel R, Larsen AR, Korman TM,
334 Stinear TP, Howden BP. 2018. Global spread of three multidrug-resistant lineages of *Staphylococcus*
335 *epidermidis*. *Nature Microbiology* 3:1175-1185.
- 336 3. Chambers HF, Deleo FR. 2009. Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nature*
337 *Reviews Microbiology* 7:629-641.
- 338 4. Lin DM, Koskella B, Lin HC. 2017. Phage therapy: An alternative to antibiotics in the age of multi-drug
339 resistance. *World Journal of Gastrointestinal Pharmacology and Therapeutics* 8:162.
- 340 5. Weber-Dąbrowska B, Jończyk-Matysiak E, Żaczek M, Łobocka M, Łusiak-Szelachowska M, Górska A.
341 2016. Bacteriophage Procurement for Therapeutic Purposes. *Frontiers in Microbiology* 7.
- 342 6. Oliveira H, Sampaio M, Melo LDR, Dias O, Pope WH, Hatfull GF, Azeredo J. 2019. *Staphylococci*
343 phages display vast genomic diversity and evolutionary relationships. *BMC Genomics* 20.
- 344 7. Valente LG, Pitton M, Fürholz M, Oberhaensli S, Bruggmann R, Leib SL, Jakob SM, Resch G, Que Y-A,
345 Cameron DR. 2021. Isolation and characterization of bacteriophages from the human skin microbiome
346 that infect *Staphylococcus epidermidis*. *FEMS Microbes* 2:xtab003.
- 347 8. Aswani V, Tremblay DM, Moineau S, Shukla SK. 2011. *Staphylococcus epidermidis* Bacteriophages
348 from the Anterior Nares of Humans. *Applied and Environmental Microbiology* 77:7853-7855.
- 349 9. Daniel A, Bonnen PE, Fischetti VA. 2007. First Complete Genome Sequence of Two *Staphylococcus*
350 *epidermidis* Bacteriophages. *Journal of Bacteriology* 189:2086-2100.
- 351 10. Gutiérrez D, Martínez B, Rodríguez A, García P. 2012. Genomic characterization of two *Staphylococcus*
352 *epidermidis* bacteriophages with anti-biofilm potential. *BMC Genomics* 13:228.
- 353 11. Melo LDR, Sillankorva S, Ackermann H-W, Kropinski AM, Azeredo J, Cerca N. 2014. Isolation and
354 characterization of a new *Staphylococcus epidermidis* broad-spectrum bacteriophage. *Journal of General*
355 *Virology* 95:506-515.
- 356 12. Gutiérrez D, Martínez B, Rodríguez A, García P. 2010. Isolation and Characterization of Bacteriophages
357 Infecting *Staphylococcus epidermidis*. *Current Microbiology* 61:601-608.
- 358 13. Fanaei Pirlar R, Wagemans J, Ponce Benavente L, Lavigne R, Trampuz A, Gonzalez Moreno M. 2022.
359 Novel Bacteriophage Specific against *Staphylococcus epidermidis* and with Antibiofilm Activity. *Viruses*
360 14:1340.

- 361 14. Philipson C, Voegtly L, Lueder M, Long K, Rice G, Frey K, Biswas B, Cer R, Hamilton T, Bishop-Lilly
362 K. 2018. Characterizing Phage Genomes for Therapeutic Applications. *Viruses* 10:188.
- 363 15. Mack D, Siemssen N, Laufs R. 1992. Parallel induction by glucose of adherence and a polysaccharide
364 antigen specific for plastic-adherent *Staphylococcus epidermidis*: evidence for functional relation to
365 intercellular adhesion. *Infect Immun* 60:2048-57.
- 366 16. Ramsey J, Rasche H, Maughmer C, Criscione A, Mijalis E, Liu M, Hu JC, Young R, Gill JJ. 2020.
367 Galaxy and Apollo as a biologist-friendly interface for high-quality cooperative phage genome
368 annotation. *PLOS Computational Biology* 16:e1008214.
- 369 17. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI,
370 Pham S, Prjibelski AD, Pyshkin AV, Sirotnik AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA.
371 2012. SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing.
372 *Journal of Computational Biology* 19:455-477.
- 373 18. Larsson A. 2014. AliView: a fast and lightweight alignment viewer and editor for large datasets.
374 *Bioinformatics* 30:3276-3278.
- 375 19. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30:2068-2069.
- 376 20. Aiewsakun P, Simmonds P. 2018. The genomic underpinnings of eukaryotic virus taxonomy: creating a
377 sequence-based framework for family-level virus classification. *Microbiome* 6.
- 378 21. Baerends RJ, Smits W, De Jong A, Hamoen LW, Kok J, Kuipers OP. 2004. Genome2D: a visualization
379 tool for the rapid analysis of bacterial transcriptome data. *Genome Biology* 5:R37.
- 380 22. Naville M, Ghuillot-Gaudeffroy A, Marchais A, Gautheret D. 2011. ARNold: A web tool for the
381 prediction of Rho-independent transcription terminators. *RNA Biology* 8:11-13.
- 382 23. Kalvari I, Nawrocki EP, Ontiveros-Palacios N, Argasinska J, Lamkiewicz K, Marz M, Griffiths-Jones S,
383 Toffano-Nioche C, Gautheret D, Weinberg Z, Rivas E, Eddy SR, Robert, Bateman A, Petrov AI. 2021.
384 Rfam 14: expanded coverage of metagenomic, viral and microRNA families. *Nucleic Acids Research*
385 49:D192-D200.
- 386 24. Chan PP, Lowe TM. 2019. tRNAscan-SE: Searching for tRNA Genes in Genomic Sequences, p 1-14
387 doi:10.1007/978-1-4939-9173-0_1. Springer New York.
- 388 25. Tynecki P, Guziński A, Kazimierczak J, Jadczuk M, Dastych J, Onisko A. 2020. PhageAI -
389 Bacteriophage Life Cycle Recognition with Machine Learning and Natural Language Processing
390 doi:10.1101/2020.07.11.198606. Cold Spring Harbor Laboratory.
- 391 26. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput.
392 *Nucleic Acids Research* 32:1792-1797.
- 393 27. Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New Algorithms and
394 Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the Performance of PhyML 3.0.
395 *Systematic Biology* 59:307-321.
- 396 28. Handke LD, Rogers KL, Olson ME, Somerville GA, Jerrells TJ, Rupp ME, Dunman PM, Fey PD. 2008.
397 <i>Staphylococcus epidermidis saeR</i> Is an Effector of Anaerobic Growth and a Mediator of Acute
398 Inflammation. *Infection and Immunity* 76:141-152.
- 399 29. Foley S, Lucchini S, Zwahlen M-C, Brüssow H. 1998. A Short Noncoding Viral DNA Element Showing
400 Characteristics of a Replication Origin Confers Bacteriophage Resistance to *Streptococcus thermophilus*.
401 *Virology* 250:377-387.
- 402 30. Da Silva Duarte V, Giaretta S, Campanaro S, Treu L, Armani A, Tarrah A, Oliveira de Paula S,
403 Giacomini A, Corich V. 2019. A Cryptic Non-Inducible Prophage Confers Phage-Immunity on the
404 *Streptococcus thermophilus* M17PTZA496. *Viruses*. 11(1):doi:10.3390/v1101007.
- 405 31. Hyman P. 2019. Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth.
406 *Pharmaceuticals* 12:35.
- 407 32. Fortier L-C, Sekulovic O. 2013. Importance of prophages to evolution and virulence of bacterial
408 pathogens. *Virulence* 4:354-365.
- 409 33. Fišarová L, Botka T, Du X, Mašlaňová I, Bárdy P, Pantůček R, Benešík M, Roudnický P, Winstel V,
410 Larsen J, Rosenstein R, Peschel A, Doškař J. 2021. *Staphylococcus epidermidis* Phages Transduce
411 Antimicrobial Resistance Plasmids and Mobilize Chromosomal Islands. *mSphere* 6.

- 412 34. Jalal ASB, Le TBK. 2020. Bacterial chromosome segregation by the ParABS system. *Open Biology* 10:200097.
- 413 35. Borysowski J, Międzybrodzki R, Górska A. 2014. *Phage therapy : current research and applications*. Caister Academic Press, Norfolk, England.
- 414 36. Howard-Varona C, Hargreaves KR, Abedon ST, Sullivan MB. 2017. Lysogeny in nature: mechanisms, impact and ecology of temperate phages. *The ISME Journal* 11:1511-1520.
- 415 37. Piligrimova EG, Kazantseva OA, Kazantsev AN, Nikulin NA, Skorynina AV, Koposova ON, Shadrin AM. 2021. Putative plasmid prophages of *Bacillus cereus* sensu lato may hold the key to undiscovered phage diversity. *Scientific Reports* 11.
- 416 38. Stella EJ, Franceschelli JJ, Tasselli SE, Morbidoni HR. 2013. Analysis of Novel Mycobacteriophages Indicates the Existence of Different Strategies for Phage Inheritance in Mycobacteria. *PLoS ONE* 8:e56384.
- 417 39. Livny J, Yamaichi Y, Waldor Matthew K. 2007. Distribution of Centromere-Like parS Sites in Bacteria: Insights from Comparative Genomics. *Journal of Bacteriology* 189:8693-8703.
- 418 40. Erdmann N, Petroff T, Funnell BE. 1999. Intracellular localization of P1 ParB protein depends on ParA and <i>parS</i>. *Proceedings of the National Academy of Sciences* 96:14905-14910.
- 419 41. Cenens W, Makumi A, Mebrhatu MT, Lavigne R, Aertsen A. 2013. Phage–host interactions during pseudolysogeny. *Bacteriophage* 3:e25029.
- 420 42. Simpson Alice E, Skurray Ronald A, Firth N. 2003. A Single Gene on the Staphylococcal Multiresistance Plasmid pSK1 Encodes a Novel Partitioning System. *Journal of Bacteriology* 185:2143-2152.
- 421 43. Abedon ST. 2009. Disambiguating bacteriophage pseudolysogeny: an historical analysis of lysogeny, pseudolysogeny, and the phage carrier state.
- 422 44. Onodera S, Olkkonen VM, Gottlieb P, Strassman J, Qiao XY, Bamford DH, Mindich L. 1992. Construction of a transducing virus from double-stranded RNA bacteriophage phi6: establishment of carrier states in host cells. *Journal of Virology* 66:190-196.
- 423 45. Łoś M, Węgrzyn G. 2012. Pseudolysogeny. *Adv Virus Res* 82:339-49.
- 424 46. Ruiz-Cruz S, Parlindungan E, Erazo Garzon A, Alqarni M, Lugli GA, Ventura M, Van Sinderen D, Mahony J. 2020. Lysogenization of a Lactococcal Host with Three Distinct Temperate Phages Provides Homologous and Heterologous Phage Resistance. *Microorganisms* 8:1685.
- 425 47. Bondy-Denomy J, Qian J, Westra ER, Buckling A, Guttman DS, Davidson AR, Maxwell KL. 2016. Prophages mediate defense against phage infection through diverse mechanisms. *The ISME Journal* 10:2854-2866.
- 426 48. Chen Y, Batra H, Dong J, Chen C, Rao VB, Tao P. 2019. Genetic Engineering of Bacteriophages Against Infectious Diseases. *Frontiers in Microbiology* 10.
- 427 49. Nair A, Khairnar K. 2019. Genetically engineered phages for therapeutics: proceed with caution. *Nature Medicine* 25:1028-1028.
- 448
- 449


450 Figure 1: Lacachita genomic map. ORFs are annotated with predicted protein products.



451

452

453 Figure 2: Phylogenetic tree of dsDNA prokaryotic viruses from GRAViTy, collapsed to focus on
 454 Lacachita and its relatives. Labels include GenBank accession numbers, family, order, and genus
 455 assignments, and phage names. The six genomes comprising the novel genus, including Lacachita, are in
 456 the blue clade.




457

0.2

458

459 Figure 3: Genomic maps of close relatives of Lacachita. ORFs are color coded according to the
460 categories of predicted protein products described in GenBank accessions. Genomes are presented using
461 the coordinate numbering system from their GenBank entries. The genomes of MF417888 and
462 NZ_CAJUVG010000006 were reversed to match the orientation of Lacachita.




463

464

465 Figure 4: Maximum likelihood tree of protein sequences similar to Lacachita's ParB protein
466 (UVD33307.1) and identified ParB proteins from *Staphylococcus* genomes. Protein names are color-
467 coded according to their source organism. Bacteria-associated proteins are shown in blue, cultured
468 phage proteins are shown in pink, and putative or uncultured phage proteins are shown in purple. Clades
469 with moderate or strong bootstrap support are shown with open (70-84.9%) or closed (85-100%)
470 circles.

471



472

473

474 Table 1: Other Proposed Members of Novel Genus

Phage Genome	Accession	Sample type	Isolation location	Length (bp)	Query cover of Lacachita	% identity with Lacachita	Phage AI Predicted Lifestyle
<i>Staphylococcus</i> phage Sazerac, complete genome	ON550478.1	cultured isolate	IL, USA	46428	94%	96.27	Temperate
<i>Staphylococcus</i> phage CUB-EPI_14, complete genome	ON325435.2	cultured isolate	Germany	46098	93%	96.19	Temperate
Uncultured Caudovirales phage clone 9S_3	MF417888.1	uncultured isolate	South Africa	45052	93%	95.53	Temperate
TPA: Myoviridae sp. isolate ct5pN1	BK030923.1	metagenome assembled genome	USA	46472	95%	98.64	Temperate
Contig of <i>Staphylococcus epidermidis</i> isolate Sep_B35_CVC_2019, whole genome shotgun sequence (proposed prophage)	NZ_CAJUV G01000006	whole genome shotgun sequence from <i>S. epidermidis</i> isolate	Portugal	46658	98%	96.47	Temperate

475

476

477 Table 2: Lacachita host range as determined by 5 μ L spots of serial dilutions of lysates.

Species	Strain	Highest dilution of Lacachita lysate that produced lysis
<i>S. epidermidis</i>	1457	10 ⁻⁵
	158-22	lysate
	B138-22	lysate
	B72-22	lysate
	B76-22	-
	B64-22	-
	NRS101(RP62a)	10 ⁻²
	ATCC12228	-
<i>S. capitnis</i>	B65-22	10 ⁻²
	B1931-21	10 ⁻²
<i>S. lungenensis</i>	B50-22	lysate
<i>S. haemolyticus</i>	B1869-21	-
	157-22	-
<i>S. hominis</i>	160-22	-
	B124-22	-
<i>S. simulans</i>	B149-22	-
	B1781-21	-
<i>S. aureus</i>	B21-11	-
	SH1000	-
	MW2	-
	N315	-
<i>S. warneri</i>	B21-22	-

478

479

Table 3: Protein Comparison

ParB Comparison				
Phage Genome	Original annotation	Accession	Query cover compared to Lacachita	% identity with Lacachita
Sazerac	putative adenine methyltransferase family protein	USL87160.1	100%	98.20%
CUB-EPI_14	DNA modification methylase	URG13538.1	100%	95.99%
Uncultured Caudovirales phage clone 9S_3	putative transferase	ASN69280.1	90%	97.79%
TPA: Myoviridae sp. isolate ct5pN1	ParB protein	DAI53229.1	100%	99.80%
Sep_B35_CVC_2019 proposed prophage	ParB N-terminal domain-containing protein	WP_2181168 39.1	52%	100%

Phage Resistance Protein Comparison				
Phage Genome	Original annotation	Accession	Query cover compared to Lacachita	% identity with Lacachita
Sazerac	hypothetical protein	USL87122.1	100%	96.89%
CUB-EPI_14	hypothetical protein	URG13503.1	100%	83.23%
Uncultured Caudovirales phage clone 9S_3	hypothetical protein	ASN69320.1	100%	88.82%
TPA: Myoviridae sp. isolate ct5pN1	resistance protein	DAI53234.1	100%	100%
Sep_B35_CVC_2019 proposed prophage	siphovirus Gp157 family protein	WP_2181168 71.1	100%	83.23%